These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 4986099)

  • 21. Estimating tissue iron burden: current status and future prospects.
    Wood JC
    Br J Haematol; 2015 Jul; 170(1):15-28. PubMed ID: 25765344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ON SOME PARTICULAR ASPECTS OF IRON KINETICS IN SUBJECTS WITH THALASSEMIA MAJOR].
    PRIOLISI A; GIUFFRE L
    Pediatria (Napoli); 1964 Jun; 72():467-92. PubMed ID: 14170507
    [No Abstract]   [Full Text] [Related]  

  • 23. [59Fe loss in the stool in various hematological disorders].
    Miura T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1968 Dec; 28(9):1288-95. PubMed ID: 5251511
    [No Abstract]   [Full Text] [Related]  

  • 24. Radio-iron content of epithelium and cell turnover in psoriasis. Iron excretion in man, II.
    Reizenstein P; Skog E; Stigell P
    Acta Derm Venereol; 1968; 48(1):70-4. PubMed ID: 4174107
    [No Abstract]   [Full Text] [Related]  

  • 25. Iron metabolism in thalassemia.
    Pootrakul P; Huebers HA; Finch CA; Pippard MJ; Cazzola M
    Birth Defects Orig Artic Ser; 1988; 23(5B):3-8. PubMed ID: 3291964
    [No Abstract]   [Full Text] [Related]  

  • 26. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.
    Breuer W; Ghoti H; Shattat A; Goldfarb A; Koren A; Levin C; Rachmilewitz E; Cabantchik ZI
    Am J Hematol; 2012 Jan; 87(1):55-61. PubMed ID: 22125177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between three radioisotope methods for measuring iron absorption.
    Lunn JA; Richmond J; Simpson JD; Leask JD; Tothill P
    Br Med J; 1967 Aug; 3(5561):331-3. PubMed ID: 6029161
    [No Abstract]   [Full Text] [Related]  

  • 29. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 30. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
    Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary iron in patients with sickle cell anamia.
    Washington R; Boggs DR
    J Lab Clin Med; 1975 Jul; 86(1):17-23. PubMed ID: 1151137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
    Nienhuis AW; Delea C; Aamodt R; Bartter F; Anderson WF
    Birth Defects Orig Artic Ser; 1976; 12(8):177-85. PubMed ID: 795481
    [No Abstract]   [Full Text] [Related]  

  • 33. Disorders of iron utilization.
    Goldberg A; Dagg HJ; Cumming RL
    Proc R Soc Med; 1970 Dec; 63(12):1232-4. PubMed ID: 5490770
    [No Abstract]   [Full Text] [Related]  

  • 34. [Disorders of iron metabolism in liver patients].
    Stromeyer G
    Internist (Berl); 1966 Jan; 7(1):33-42. PubMed ID: 4861683
    [No Abstract]   [Full Text] [Related]  

  • 35. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C; Rachmilewitz EA
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cutaneous clearance of iron in healthy and anemic children].
    Mollica F; Musumeci S
    Pediatria (Napoli); 1970; 78(5):854-67. PubMed ID: 5517238
    [No Abstract]   [Full Text] [Related]  

  • 37. Excretion of endogenous non-haem iron by the gastrointestinal tract in human subjects and its influence on the size of body store of iron with particular reference to coeliac disease.
    Singh AK
    Br J Haematol; 1970 Jun; 18(6):597-609. PubMed ID: 5428620
    [No Abstract]   [Full Text] [Related]  

  • 38. Can iron chelators influence the progression of atherosclerosis?
    Marx JJ; Kartikasari AE; Georgiou NA
    Hemoglobin; 2008; 32(1-2):123-34. PubMed ID: 18274990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alteration in cobalt absorption in patients with disorders of iron metabolism.
    Valberg LS; Ludwig J; Olatunbosun D
    Gastroenterology; 1969 Feb; 56(2):241-51. PubMed ID: 5764593
    [No Abstract]   [Full Text] [Related]  

  • 40. Iron transport across rabbit allantoic placenta.
    Larkin EC; Weintraub LR; Crosby WH
    Am J Physiol; 1970 Jan; 218(1):7-11. PubMed ID: 5409895
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.